Jessica Yaniv (whose legal name is Jessica Simpson) is a Canadian transgender activist in British Columbia who is best known for filing at least fifteen complaints of discrimination on the basis of gender identity against various beauty salons after they refused to wax her male genitalia. The complaints were filed with the British Columbia Human Rights Tribunal in 2018 and 2019. It was the first major case of alleged transgender discrimination in retail in Canada. In 2019, the Tribunal rejected her initial complaints and ruled Yaniv had racist motives. In following years, Yaniv has also gone on to make additional complaints of discrimination, libel and privacy breach.

CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to BBIBP-CorV and BBV152, other inactivated-virus COVID-19 vaccines. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept. A real-world study of millions of Chileans who received CoronaVac found it 65% effective against symptomatic COVID-19, 87% against hospitalization, 90% against ICU admissions, and 86% against deaths. In Indonesia, real world data showed 94% of inoculated health care workers protected against symptomatic infection by the vaccine, beating results in clinical trials. Phase III results from Brazil had previously shown 50.7% efficacy at preventing symptomatic infections and 83.7% effective in preventing mild cases needing treatment. Efficacy against symptomatic infections increased to 62.3% with an interval of 21 days or more between the doses. Final Phase III results from Turkey announced on 3 March 2021 showed an efficacy of 84%. A trial conducted in Serrana, São Paulo where athorites attempted vaccinate the entire population using CoronaVac. After three-quarters of the population in Serrana received CoronaVac, preliminary results show that deaths fell by 95%, hospitalizations by 86% and symptomatic cases by 80%. Politicization, transparency issues and some incomplete trial data in Brazil contributed to a lack of trust in CoronaVac there. CoronaVac is being used in vaccination campaigns in various countries in Asia, South America, North America, and Europe. By April 2021, Sinovac had a production capacity of 2 billion doses a year and had delivered 600 million total doses. It is currently being manufactured at several facilities in China, with planned overseas manufacture in Brazil in September 2021 and eventually in Egypt. On June 1 2021, the World Health Organization approved the vaccine for use in COVAX.